126.75 -0.08 (-0.06%)
After hours: 6:27PM EDT
|Bid||126.75 x 100|
|Ask||127.00 x 100|
|Day's Range||125.78 - 127.30|
|52 Week Range||122.15 - 148.32|
|PE Ratio (TTM)||267.57|
|Earnings Date||Jul 17, 2018|
|Forward Dividend & Yield||3.36 (2.57%)|
|1y Target Est||149.05|
Kentucky Governor Matt Bevin discusses his state District Attorney suing Johnson & Johnson for contributing to the opioid epidemic through deceptive marketing.
Johnson & Johnson (JNJ) reported 12.6% growth in its revenues to $20.0 billion during 1Q18 as compared to revenues of $17.8 billion during 1Q17. The company surpassed Wall Street analyst estimates for EPS (earnings per share) and revenues and reported EPS of $2.06 on revenues of $20.0 billion during 1Q18 against estimates for EPS of $2.00 on revenues of $19.4 billion during 1Q17.
Eli Lilly & Co. (LLY) is a leading US-based pharmaceutical company with a product portfolio covering human health products and animal health products. Eli Lilly is set to release its 1Q18 earnings on April 24.
As discussed in the previous article, analysts expect a 2.2% decrease in GlaxoSmithKline’s (GSK) 1Q18 revenues to 7.2 billion pounds due to the impact of divestitures, the negative impact of foreign exchange, and lower sales of some products.
Merck’s (MRK) Relebactam is an investigational beta-lactamase inhibitor for the treatment of certain forms of imipenem-non-susceptible bacterial infections.
Like many combat veterans, Steve Hammond struggled for years after returning to civilian life, battling physical injuries that made it difficult to find a job and left him contemplating suicide. Now the 61-year-old father of two is thriving as a team leader with Britain's Bravest Manufacturing Company (BBMC), one of a growing number of socially-minded companies providing jobs for people marginalised from the traditional workforce. "It gives people with a disability or mental health issues a purpose in life," Hammond, who was wounded in the Falklands War, told the Thomson Reuters Foundation.
A new wave of innovation will change several of America's most established industries. Here are three important takeaways for investors.
Earnings per share were higher despite a higher tax rate and a lower contribution from other income. What we didn’t like about the first quarter: 1) the pharma mix was not optimal, as key drugs Actelion, Darzalex, and Xarelto all missed our estimate. U.S. Remicade was down 16% Y/Y, in line with our estimate, but we were hoping for better.
After a spell of high volatility driven by uncertainty over global trade policy and the threat of rise in prices of essential commodities, Wall Street is looking for some respite in the upcoming earnings season. Given the positive trend, investing in blue-chip stocks that are likely to make the most of the earnings season seems judicious. This is because such stocks are positioned to report impressive earnings results as they mostly have a strong balance sheet and solid cash flow.
Novartis (NVS) and J&J (JNJ) deliver strong Q1 results. Merck (MRK) and Bristol Myers (BMY) present lung cancer data at AACR.
Pharmaceutical and biotech stocks are rarely seen as effective dividend stocks. Although drugs are also relatively non-cyclical these stocks are often impacted by ever-changing regulatory environment and the strength ofRead More...
issues were still top of mind to just about everyone as investors continued to drive the stock down as well. It's tough for some investors to find a positive view of the Seattle-based coffee house company. It's been trading sideways for close to three years, producing a 2% return over the last 12 months compared with 15% for the S&P and a somewhat pricey 21 times P/E multiple for a food and beverage company, all of which make an unappetizing menu choice for investors, never mind the company's moral and ethical dilemmas, says Stephen Guilfoyle.
The major equity indexes barely moved today, as a postearnings drop from International Business Machines (IBM) was canceled out by gains from Textron (TXT), Intuitive Surgical (ISRG), and others. Ultimately, it shows once again that it's as much a market of stocks as it is a stock market. The Dow Jones Industrial Average dropped 38.56 points, or 0.2%, to 24,748.07, while the S&P 500 ticked up 0.1% to 2708.64, and the Nasdaq Composite advanced 0.2% to 7295.24.
"I'm not on board with just about anything that he does," Gov. Matt Bevin said of Kentucky Attorney General Andy Beshear.
Kentucky's attorney general on Wednesday sued Johnson & Johnson, accusing the pharmaceutical manufacturer of devising a deceptive marketing scheme that mischaracterized the risk of opioid abuse and addiction. The lawsuit by Kentucky Attorney General Andy Beshear was his fifth to date seeking to hold a drug manufacturer or distributor responsible for its role in the national opioid epidemic.
The Dow Jones Industrial Average on Wednesday morning was wrestling with sharp declines in IBM and Johnson & Johnson. Shares of International Business Machines Corp. were off 7.2%, or about $11.50, which equates to a drop of about 80 points, while J&J's stock was contributing a further 24-point retreat in the benchmark, down 2.7%, or about $3.50, in recent action. Overall, the Dow was still managing to rise by about 24 points, or less than 0.1%, at 24,802, with J&J and IBM's tumble slightly offset by gains in Home Depot Inc. Caterpillar Inc. and Boeing Co. 's stocks.